MOTS-c: Legal Status, Evidence and Side Effects

MOTS-c is sold online as a "mitochondrial" peptide for fat loss, insulin resistance and longevity. Here is what FDA's 2026 review found, what the law allows, and what is still unknown.

Legal status of MOTS-c

Waiting on FDA after a favorable vote

MOTS-c won a favorable but nonbinding advisory committee vote in July 2026, and FDA has not acted on it ^[3]. It still cannot be legally compounded or sold as a drug ^[1].

FDA status

FDA removed it from Category 2 in April 2026 because the nominators withdrew their nominations ^[7]. That removal did not make it legal to compound ^[9]. FDA now lists it as "nominated but withdrawn," which is outside every category ^[8]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today ^[1]. FDA found no clinical studies of MOTS-c, only rodent and lab data ^[4].

Advisory committee

On July 23, 2026, the committee voted 7 yes, 5 no and 2 abstain to recommend adding MOTS-c to the 503A bulks list ^[2]. The committee reviewed it for obesity and osteoporosis ^[14]. FDA staff had recommended against listing it ^[4]. FDA has not posted its own vote count on the meeting page ^[14]. Advisory committee votes are not binding. Nothing changes until FDA acts ^[11].

FDA-approved products

None. We found no FDA-approved drug that contains MOTS-c.

Sports (WADA)

Prohibited at all times under class S4 as an AMPK activator. MOTS-c is named ^[5].

What happens next

To add it to the 503A bulks list, FDA must go through notice-and-comment rulemaking, starting with a proposed rule. FDA could also place it in Category 1 or announce enforcement discretion in the meantime ^[11]. As of Oct 16, 2026, FDA had not started rulemaking or moved any of these peptides to Category 1 ^[3]. HHS has sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House budget office for review. Holland & Knight dates that submission Oct 14, 2026 ^[3], while the AP reported it appeared on a government website on Oct 15 ^[12]. The policy has not been issued and its text is not public ^[3]; reporting on Oct 21, 2026 still described it as under review ^[17]. Reports say it would cover some popular peptides, but we could not confirm whether MOTS-c is one of them ^[12]. One law firm says there is no reliable timetable for final action ^[11]. A drug safety group petitioned FDA on Oct 16, 2026 not to allow it ^[13].

Checked against FDA sources on Oct 24, 2026. We update this box when FDA acts. Report a change: [email protected].

Where MOTS-c stands with FDA

MOTS-c sat in FDA's Category 2, substances with significant safety risks, from 2023 until April 2026, when FDA removed it along with 11 other peptides because the nominators withdrew ^{[6] [7]}. Removal did not open a legal door: it is now on a "nominated but withdrawn" list that gives pharmacies no cover ^{[8] [9]}. To be compounded, a bulk ingredient needs a USP monograph, a place in an approved drug, or a spot on the bulks list, and MOTS-c has none of these ^{[10] [1]}.

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 7 yes, 5 no and 2 abstain to recommend adding it to the bulks list ^[2]. FDA staff had advised against it ^[4]. The vote is nonbinding; FDA must still propose a rule, use Category 1, or announce enforcement discretion ^[11]. None of that had happened by Oct 16, 2026 ^[3].

Two developments are pulling in opposite directions. HHS sent an interim peptide access policy to the White House budget office in October 2026, with no public text and no confirmed list of peptides ^{[3] [12]}. And on Oct 16, 2026 the Partnership for Safe Medicines petitioned FDA to keep MOTS-c and six other peptides off the market ^[13].

What MOTS-c is

FDA describes MOTS-c as "a peptide consisting of 16 amino acids" ^[4]. Its full name, mitochondrial open reading frame of the 12S rRNA-c, reflects that its code sits in mitochondrial DNA rather than the cell nucleus ^[5]. The nominators listed insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity as uses ^[4]. FDA put two of those, obesity and osteoporosis, to the committee ^[14].

Mouse and rat results, not human ones

The animal findings FDA cited are real but narrow. Male mice given MOTS-c on a high-fat diet "gained significantly less body weight than untreated male mice fed the same diet" ^[4]. In lab dishes, it promoted bone formation in rat bone marrow stem cells ^[4]. Those are early signals.

For people, FDA wrote: "we did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans" ^[4]. No published trial shows weight loss, better blood sugar or stronger bones in people taking it. Growth hormone peptides such as CJC-1295 and ipamorelin are also sold for fat loss, and they cannot be compounded either. If you want a peptide with human weight loss data, the approved GLP-1 drugs have large trials; see GLP-1 costs and tirzepatide.

It breaks down fast in human blood

FDA cited a lab study "reporting that MOTS-c is quickly hydrolyzed in human blood" ^[4]. Hydrolyzed means broken apart. That raises a basic question no study has answered: how much of an injected dose stays intact long enough to do anything.

MOTS-c side effects

No human safety data exist, so no side effect rates exist ^[4]. FDA's main stated concern is the potential for immunogenicity when it is injected, as proposed, meaning the body could react to the peptide or its impurities ^[4]. FDA's safety page says it has not identified any human exposure data for products containing MOTS-c ^[8].

Banned for athletes as an AMPK activator

The 2026 WADA Prohibited List names MOTS-c under class S4, hormone and metabolic modulators, as an activator of the enzyme AMPK ^[5]. Class S4 is banned at all times ^[5].

Can you get MOTS-c legally?

"Research use only" vials are not legal for personal use; FDA has rejected that label in warning letters ^[15]. Peptides with a legal route today are on our legal peptide price tracker. For longevity testing that is legal and priced, see our longevity guide. The other peptides from the same vote are on our peptide status tracker, including BPC-157.

Dated changes

• Oct 16, 2026: The Partnership for Safe Medicines filed a citizen petition asking FDA not to allow compounding of this and six other peptides, by rule, Category 1 placement or enforcement discretion ^[13].
• Oct 14, 2026: HHS sent an interim peptide access policy to the White House budget office for review, per Holland & Knight ^[3]. The AP reported it appeared on Oct 15 ^[12]. It has not been issued ^[3].
• Jul 23, 2026: On July 23, 2026, the committee voted 7 yes, 5 no and 2 abstain to recommend adding MOTS-c to the 503A bulks list ^[2].
• May 11, 2026: FDA staff briefing documents recommended against adding it to the 503A bulks list ^[4].
• Apr 22, 2026: The removal took effect around this date. FDA now lists it as nominated but withdrawn, which does not allow compounding ^{[8] [9]}.
• Apr 15, 2026: FDA gave seven days' notice that it would remove 12 peptides, including this one, from Category 2 because the nominators withdrew ^[7].
• Sep 29, 2023: FDA placed it in Category 2, citing significant safety risks ^[6].

The other peptides FDA's committee weighed in July 2026: TB-500, KPV, Semax, epitalon and DSIP. For approved peptide drugs, see PT-141 and SS-31.

Method

We rechecked FDA's categories document, FDA's advisory committee pages and recent coverage on Oct 24, 2026 ^{[1] [16]}. Vote counts come from law firm reports because FDA has not posted minutes for July 2026 ^{[2] [14]}. We do not link to sellers. More in our editorial standards.